Logo - springer
Slogan - springer

Biomedical Sciences - Pharmacology & Toxicology | Journal of Medical Toxicology

Journal of Medical Toxicology

Journal of Medical Toxicology

Editor-in-Chief: Mark B. Mycyk

ISSN: 1556-9039 (print version)
ISSN: 1937-6995 (electronic version)

Journal no. 13181

80,33 € Personal Rate e-only
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

1 Volume(-s) with 4 issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy

Instructions for Authors

Types of papers 

Types of papers

The Journal of Medical Toxicology publishes original articles, illustrative cases, review articles, and other special features. Please note that JMT only accepts manuscripts written in proper English.
For details of the types of paper we publish, see below.
For any and all other manuscript inquiries, please contact jmtinfo@acmt.net.

Manuscript Submission 

Manuscript Submission

Submission of a manuscript implies: that the work described has not been published before; that it is not under consideration for publication anywhere else; that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.


Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.

Online Submission

Please follow the hyperlink “Submit online” on the right and upload all of your manuscript files following the instructions given on the screen.

Title page 

The title page should include:
Sources of funding for project.
Conflict delineations
Previous presentation of data at meetings or in abstract form
Word count of manuscript, not counting title page or abstract
Three to five “key words” acceptable for National Library of Medicine indexing
- The name(s) of the author(s)
- A concise and informative title
- The affiliation(s) and address(es) of the author(s)
- The e-mail address, telephone and fax numbers of the corresponding author


All submitted manuscripts, with the exception of submissions to The Poison Pen, should be accompanied by an abstract limited to 250 words. The abstract should be structured using the subheadings: Introduction, Methods, Results, and Conclusions (for original research); Introduction, Case Report(s), Discussion (for descriptive reports); or Introduction, Discussion, Conclusions (for reviews). References should not be cited in the abstract. Use of abbreviations and acronyms should be limited.


Please provide 4 to 6 keywords which can be used for indexing purposes.


Text Formatting
Manuscripts should be submitted in Word.
*Use a normal, plain font (e.g., 10-point Times Roman) for text.
*Use italics for emphasis.
*Use the automatic page numbering function to number the pages.
*Do not use field functions.
*Use tab stops or other commands for indents, not the space bar.
*Use the table function, not spreadsheets, to make tables.
*Use the equation editor or MathType for equations.
*Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).
*All submissions should be double-spaced for readability.
Manuscripts with mathematical content can also be submitted in LaTeX.
LaTeX macro package (zip, 182 kB)
Please use no more than three levels of displayed headings.
Abbreviations should be defined at first mention and used consistently thereafter.
Footnotes can be used to give additional information, which may include the citation of a reference included in the reference list. They should not consist solely of a reference citation, and they should never include the bibliographic details of a reference. They should also not contain any figures or tables.
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the authors of the article are not given reference symbols.
Always use footnotes instead of endnotes.
Acknowledgments of people, grants, funds, etc. should be placed in a separate section on the title page. The names of funding organizations should be written in full.


  • All tables are to be numbered using Arabic numerals.
  • Tables should always be cited in text in consecutive numerical order.
  • For each table, please supply a table caption (title) explaining the components of the table.
  • Identify any previously published material by giving the original source in the form of a reference at the end of the table caption.
  • Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body.



Reference citations in the text should be identified by numbers in square brackets. Some examples:
1. Negotiation research spans many disciplines [3].
2. This result was later contradicted by Becker and Seligman [5].
3. This effect has been widely studied [1-3, 7].

Reference list

The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a reference list.
The entries in the list should be numbered consecutively.
  • Journal article
    Smith JJ. The world of science. Am J Sci. 1999;36:234–5.
  • Article by DOI
    Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. J Mol Med. 2000; https://doi.org/10.1007/s001090000086
  • Book
    Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of common illness. 3rd ed. Oxford: Blackwell Science; 1998.
  • Book chapter
    Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, Danielli JF, Jeon KW, editors. International review of cytology. London: Academic; 1980. pp. 251–306.
  • Online document
    Doe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of Chemistry. 1999. http://www.rsc.org/dose/title of subordinate document. Accessed 15 Jan 1999.
Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see
If you are unsure, please use the full journal title.
For authors using EndNote, Springer provides an output style that supports the formatting of in-text citations and reference list.

Ethical Responsibilities of Authors 

This journal is committed to upholding the integrity of the scientific record. As a member of the Committee on Publication Ethics (COPE) the journal will follow the COPE guidelines on how to deal with potential acts of misconduct.
Authors should refrain from misrepresenting research results which could damage the trust in the journal, the professionalism of scientific authorship, and ultimately the entire scientific endeavour. Maintaining integrity of the research and its presentation is helped by following the rules of good scientific practice, which include*:
  • The manuscript should not be submitted to more than one journal for simultaneous consideration.
  • The submitted work should be original and should not have been published elsewhere in any form or language (partially or in full), unless the new work concerns an expansion of previous work. (Please provide transparency on the re-use of material to avoid the concerns about text-recycling (‘self-plagiarism’).
  • A single study should not be split up into several parts to increase the quantity of submissions and submitted to various journals or to one journal over time (i.e. ‘salami-slicing/publishing’).
  • Concurrent or secondary publication is sometimes justifiable, provided certain conditions are met. Examples include: translations or a manuscript that is intended for a different group of readers.
  • Results should be presented clearly, honestly, and without fabrication, falsification or inappropriate data manipulation (including image based manipulation). Authors should adhere to discipline-specific rules for acquiring, selecting and processing data.
  • No data, text, or theories by others are presented as if they were the author’s own (‘plagiarism’). Proper acknowledgements to other works must be given (this includes material that is closely copied (near verbatim), summarized and/or paraphrased), quotation marks (to indicate words taken from another source) are used for verbatim copying of material, and permissions secured for material that is copyrighted.
  • Important note: the journal may use software to screen for plagiarism.
  • Authors should make sure they have permissions for the use of software, questionnaires/(web) surveys and scales in their studies (if appropriate).
  • Authors should avoid untrue statements about an entity (who can be an individual person or a company) or descriptions of their behavior or actions that could potentially be seen as personal attacks or allegations about that person.
  • Research that may be misapplied to pose a threat to public health or national security should be clearly identified in the manuscript (e.g. dual use of research). Examples include creation of harmful consequences of biological agents or toxins, disruption of immunity of vaccines, unusual hazards in the use of chemicals, weaponization of research/technology (amongst others).
  • Authors are strongly advised to ensure the author group, the Corresponding Author, and the order of authors are all correct at submission. Adding and/or deleting authors during the revision stages is generally not permitted, but in some cases may be warranted. Reasons for changes in authorship should be explained in detail. Please note that changes to authorship cannot be made after acceptance of a manuscript.
Upon request authors should be prepared to send relevant documentation or data in order to verify the validity of the results presented. This could be in the form of raw data, samples, records, etc. Sensitive information in the form of confidential or proprietary data is excluded.
*All of the above are guidelines and authors need to make sure to respect third parties rights such as copyright and/or moral rights.
If there is suspicion of misbehavior or alleged fraud the Journal and/or Publisher will carry out an investigation following COPE guidelines. If, after investigation, there are valid concerns, the author(s) concerned will be contacted under their given e-mail address and given an opportunity to address the issue. Depending on the situation, this may result in the Journal’s and/or Publisher’s implementation of the following measures, including, but not limited to:
  • If the manuscript is still under consideration, it may be rejected and returned to the author.
  • If the article has already been published online, depending on the nature and severity of the infraction:
    - an erratum/correction may be placed with the article
    - an expression of concern may be placed with the article
    - or in severe cases retraction of the article may occur. The reason will be given in the published erratum, expression of concern or retraction note. Please note that retraction means that the article is maintained on the platform, watermarked “retracted” and the explanation for the retraction is provided in a note linked to the watermarked article.
  • The author’s institution may be informed
  • A notice of suspected transgression of ethical standards in the peer review system may be included as part of the author’s and article’s bibliographic record.

Fundamental errors

Authors have an obligation to correct mistakes once they discover a significant error or inaccuracy in their published article. The author(s) is/are requested to contact the journal and explain in what sense the error is impacting the article. A decision on how to correct the literature will depend on the nature of the error. This may be a correction or retraction. The retraction note should provide transparency which parts of the article are impacted by the error.

Suggesting / excluding reviewers

Authors are welcome to suggest suitable reviewers and/or request the exclusion of certain individuals when they submit their manuscripts. When suggesting reviewers, authors should make sure they are totally independent and not connected to the work in any way. It is strongly recommended to suggest a mix of reviewers from different countries and different institutions. When suggesting reviewers, the Corresponding Author must provide an institutional email address for each suggested reviewer, or, if this is not possible to include other means of verifying the identity such as a link to a personal homepage, a link to the publication record or a researcher or author ID in the submission letter. Please note that the Journal may not use the suggestions, but suggestions are appreciated and may help facilitate the peer review process.

After acceptance 

Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order OpenChoice, offprints, or printing of figures in color.
Once the Author Query Application has been completed, your article will be processed and you will receive the proofs.

Copyright transfer

Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws.


Offprints can be ordered by the corresponding author.

Color illustrations

Online publication of color illustrations is free of charge. For color in the print version, authors will be expected to make a contribution towards the extra costs.

Proof reading

The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.
After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.

Online First

The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.

Open Choice 

Open Choice allows you to publish open access in more than 1850 Springer Nature journals, making your research more visible and accessible immediately on publication.
Article processing charges (APCs) vary by journal – view the full list
  • Increased researcher engagement: Open Choice enables access by anyone with an internet connection, immediately on publication.
  • Higher visibility and impact: In Springer hybrid journals, OA articles are accessed 4 times more often on average, and cited 1.7 more times on average*.
  • Easy compliance with funder and institutional mandates: Many funders require open access publishing, and some take compliance into account when assessing future grant applications.
It is easy to find funding to support open access – please see our funding and support pages for more information.
*) Within the first three years of publication. Springer Nature hybrid journal OA impact analysis, 2018.

Copyright and license term – CC BY

Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License.

Scientific style 

Generic names of drugs and pesticides are preferred; if trade names are used, the generic name should be given at first mention.

Integrity of Research and Reporting 

*All authors must complete the Uniform Disclosure available at www.icmje.org/coi_disclosure.pdf ).*
Uniform Requirements for Manuscripts: “Preparing a Manuscript for Submission to Biomedical Journals” and “Authorship and Contributorship” accessible at http://www.icmje.org/urm_main.html. Although all manuscripts, except for selected editorial features, are subject to peer review, the responsibility for the accuracy and legitimacy of the scientific content of the manuscripts rests with the authors. It is also the responsibility of the authors to notify the editor in writing of all potentially perceived conflicts of interest, financial or otherwise (see also Conflicts of Interest below)
Protection of Human Subjects
It is the authors’ responsibilities to ensure that all research protocols and manuscripts, including case reports, have been properly reviewed for adequate protection of human subjects as required by the authors’ institution(s). Such protections, as relevant, should be described in the Methods of the manuscript. All manuscripts must by compliant with existing standards for protection of protected health information (e,g., HIPAA).
Protection of Animals in Research
It is the authors’ responsibility to ensure that all research manuscripts involving animal experimentation have followed appropriate procedures. When reporting experiments on animals, authors should indicate that they followed institutional and/or national guidelines for the care and use of laboratory animals. Such statements should be included in the Methods section.
Conflicts of Interest
The Journal expects all authors to disclose all relevant financial relationships with all companies, organizations, or individuals regarding products discussed in a manuscript. Every author is expected to disclose individually each real or perceived potential conflicts. All authors must complete the Uniform Disclosure available at www.icmje.org/coi_disclosure.pdf ).
Reporting of randomized controlled trials must conform to the CONSORT statement (http://www.consort- statement.org/) and include a flow chart describing patient progress throughout the trial. Resuscitation studies should follow the applicable Utstein criteria when appropriate. We support consensus-based methodologic standards for other study types
Informed Consent
For studies with human subjects, please include the following statement before the References section:
'All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.'
Any experimental protocol must be approved, and owing to US regulations (the recent Health Insurance Portability and Accountability Act - HIPAA) even studies without any experimental protocol merely reporting patients or patient material require approval; these regulations require review for any studies involving patient identity, including retrospective chart, radiographic reviews, or removed tissues or materials.
If any identifying information about patients is included in the article, the following sentence should also be included:
'Additional informed consent was obtained from all patients for which identifying information is included in this article.'
Follow the below link for Springer's Informed Consent Statement:
Animal Studies
For studies with animals, include the following sentence in the manuscript before the References section:
'All institutional and national guidelines for the care and use of laboratory animals were followed.'
If the authors did not carry out animal and/or human studies as part of their article they must include the following statement in the manuscript before the References section:
'No animal or human studies were carried out by the authors for this article'
The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the above-mentioned requirements
Follow the below link for Springer's Animal and Human Rights Statement

Conflict of Interest Disclosure 

All authors must complete the Uniform Disclosure available at www.icmje.org/coi_disclosure.pdf.
When authors submit a manuscript, they are responsible for disclosing all financial and personal relationships that might bias their work. To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist. Each author must indicate whether or not they have a financial relationship with the organization that sponsored the research. For each source of funds, both the research funder and the grant number should be given.
Potential conflicts of interest exist when an author is related to a for-profit company or institution in any of the following ways:
1. Employment
2. Consultancies in the last 3 years (please list)
3. Honoraria in the last 3 years (please list)
4. Stock ownership/ options other than mutual funds (current; please list)
5. Expert testimony in the last 3 years (please list)
6. Grants received in the last 3 years (please list)
7. Grants pending (please list)
8. Patents received
9. Patents pending
10. Royalties (describe)
11. Other relationships (please specify)
Conflict of interest statements should be present on every manuscript before the References section. The statement should mention each author separately by name.
Recommended wording is as follows:
Author X declares that he has no conflict of interest.
Author Y has received research grants from Drug Company A.
Author Z has received a speaker honorarium from Drug Company B and owns stock in Drug Company C.
If multiple authors declare no conflict, this can be done in one sentence:
Author X, Author Y and Author Z declare that they have no conflict of interest.
Follow the below link for Springer's Conflict of Interest Statement:

English Language Editing 

For editors and reviewers to accurately assess the work presented in your manuscript you need to ensure the English language is of sufficient quality to be understood. If you need help with writing in English you should consider:
  • Asking a colleague who is a native English speaker to review your manuscript for clarity.
  • Visiting the English language tutorial which covers the common mistakes when writing in English.
  • Using a professional language editing service where editors will improve the English to ensure that your meaning is clear and identify problems that require your review. Two such services are provided by our affiliates Nature Research Editing Service and American Journal Experts. Springer authors are entitled to a 10% discount on their first submission to either of these services, simply follow the links below.
Please note that the use of a language editing service is not a requirement for publication in this journal and does not imply or guarantee that the article will be selected for peer review or accepted.
If your manuscript is accepted it will be checked by our copyeditors for spelling and formal style before publication.


● 请一位以英语为母语的同事审核您的稿件是否表意清晰。
● 查看一些有关英语写作中常见语言错误的教程。
● 使用专业语言编辑服务,编辑人员会对英语进行润色,以确保您的意思表达清晰,并识别需要您复核的问题。我们的附属机构 Nature Research Editing Service 和合作伙伴 American Journal Experts 即可提供此类服务。


・プロの英文校正サービスを利用する。校正者が原稿の意味を明確にしたり、問題点を指摘し、英語の質を向上させます。Nature Research Editing Service とAmerican Journal Experts の2つは弊社と提携しているサービスです。Springer の著者は、いずれのサービスも初めて利用する際には10%の割引を受けることができます。以下のリンクを参照ください。


영어 원고의 경우, 에디터 및 리뷰어들이 귀하의 원고에 실린 결과물을 정확하게 평가할 수 있도록, 그들이 충분히 이해할 수 있을 만한 수준으로 작성되어야 합니다. 만약 영작문과 관련하여 도움을 받기를 원하신다면 다음의 사항들을 고려하여 주십시오:
• 귀하의 원고의 표현을 명확히 해줄 영어 원어민 동료를 찾아서 리뷰를 의뢰합니다.
• 영어 튜토리얼 페이지에 방문하여 영어로 글을 쓸 때 자주하는 실수들을 확인합니다.
• 리뷰에 대비하여, 원고의 의미를 명확하게 해주고 리뷰에서 요구하는 문제점들을 식별해서 영문 수준을 향상시켜주는 전문 영문 교정 서비스를 이용합니다. Nature Research Editing Service와 American Journal Experts에서 저희와 협약을 통해 서비스를 제공하고 있습니다. Springer 저자들이 본 교정 서비스를 첫 논문 투고를 위해 사용하시는 경우 10%의 할인이 적용되며, 아래의 링크를 통하여 확인이 가능합니다.
영문 교정 서비스는 게재를 위한 요구사항은 아니며, 해당 서비스의 이용이 피어 리뷰에 논문이 선택되거나 게재가 수락되는 것을 의미하거나 보장하지 않습니다.
원고가 수락될 경우, 출판 전 저희측 편집자에 의해 원고의 철자 및 문체를 검수하는 과정을 거치게 됩니다.

Toxicology Investigations 

A statement of institutional review board (IRB) approval or exemption from full review is required for all research involving human subjects or their data.
Reports of original research studies should follow the "general guidelines" format when applicable and should be between 2500 and 4000 words in length and up to 50 references and 5 figures or tables. A statement of institutional review board (IRB) approval or exemption from full review is required for all research involving human subjects or their data.

Toxicology Reviews  

Review articles may be solicited by the Review Editor, but uncommissioned material is encouraged. Please contact the Editor (jmtinfo@acmt.net) before writing a review for the Journal to ensure that the topic is appropriate for the Journal and does not conflict with another pending or published review. Guidelines for Reviews have been published in the journal and must be followed (http://www.springer.com/cda/content/document/cda_downloaddocument/10.1007%252Fs13181-012-0234-2.pdf?SGWID=0-0-45-1364947-p173916204).

Preliminary Research: Research Concepts 

This section is peer-reviewed and allows expedited review of papers in an attempt to aid in securing extramural funding. For further details, see Bird SB, "Research Concepts, Collaboration, and JMT," JMT 6.1:1-2.
Submissions are limited to 5000 words or less
Authors must recommend two reviewers with experience as principal investigators of extramurally funded research or NIH scientific reviewers
Submissions require a paragraph describing the NIH or other extramural program announcement or request for application to which the submission responds
Before submitting to this section, please contact the Editor, (jmtinfo@acmt.net).

Toxicology Observations (Case Reports) 

1. The title should reveal the unusual aspect of the case.
2. The case should describe a unique or rare clinical finding or toxicological disease process of interest and value to JMT readers. Cases describing unique pharmacokinetic data, analytical methods, diagnostic tests, or therapeutic modalities are also appropriate.
3. The introduction should provide a brief background on the topic and explain why the report is of value.
4. The case must be well documented and include all relevant clinical information. Most important, there should be laboratory confirmation of the agent ingested whenever possible, with an attempt to exclude other possible causes of the finding or disease process. Credible corroborative evidence should be presented in all cases. Reports relying solely on patient history or proximity to a toxin (e.g., presence of pill bottles) are not generally acceptable. For fatalities, postmortem examination and forensic toxicology results are highly desirable.
5. The discussion should focus on the unique aspect of the case being presented. Plausibility should be addressed, with potential mechanisms for the clinical finding or drug effect provided. If the finding or condition is not consistent with what we already know about the toxicological agent involved, this should also be addressed in the discussion.
6. Include a concise review of other relevant medical literature or similar case reports in the discussion. This should not be a review of all available literature.
7. Address limitations of the report, including other possible causes of the finding or condition, if they exist.
8. Toxicology Observations should be approximately 1500 words with 10 references and no more than 3 figures or tables.
For an expanded discussion of a well written toxicology case report, please see "Ruha AM: The Case Report: A Tool for the Toxicologist. Journal of Medical Toxicology 2009; 5:1-2.
As of 1 July 2015, JMT will require informed consent for submitted case reports. Please see our 2014 commentary on informed consent. Neavyn M, Murphy C. Coming to a consensus on informed consent. J Med Toxicol 2014;10(4):337-9. DOI 10.1007/s13181-014-0421-4
Instructions for Obtaining Informed Consent
1. Attempt to obtain consent to publish for all case reports. Consent is required for case reports with highly identifiable patient information/characteristics or cases of child abuse, elder abuse, or those involving criminal investigation. If consent is unobtainable (not refused), please make every effort to anonymize the case report and include a formal statement regarding the circumstances making consent unobtainable in a cover letter to the editor with your submission. The section editor and editor-in-chief will make decisions regarding these cases.
2. Consent forms from the primary author(s) institution are acceptable. Authors that do not have access to an institutional consent form should use the appropriate template provided by the World Health Organization found here: http://www.who.int/rpc/research_ethics/ informed_consent/en/
3. Authors are to obtain consent, provide a statement in the manuscript documenting patient consent obtained, and maintain copies of the signed consent form for a period of 7 years. In an effort to maintain patient privacy, copies of actual forms will only be requested for submission at the discretion of the editor-in-chief.
Beginning July 1, 2015 all Case Report submissions must be accompanied by a signed consent form. Click below to download form:

Toxicology Case Files 

Toxicology Case Files
Section Editor: Jeffrey Suchard, MD
"Case Files” is a recurring feature of JMT in which Medical Toxicology fellowship programs present clinical cases that highlight important, interesting, and/or controversial issues in the diagnosis and management of poisoned patients. Each “Case Files” article is an extended case report; as the case unfolds, various issues arise, which are discussed in a “question & answer” format that is intended to read like an erudite discussion between a Medical Toxicology fellow and their attending physician. Case Files are generally solicited by the Section Editor, Jeffrey Suchard (jsuchard@uci.edu). Please contact him directly before submitting to this section.
Case Selection:
Any case that highlights important, interesting, or controversial issues in the diagnosis and management of poisoned patients could potentially be used as the basis for a “Case Files” article. The cases don’t have to be particularly amazing, like CPC cases often are. In fact, cases involving more common toxins may be preferable, because more commonly-encountered clinical questions can be posed (and discussed), and more published research will be available to use as references.
Each “Case Files” manuscript will be a co-authored manuscript. The authors will include one Medical Toxicology fellow and one Medical Toxicology attending physician associated with the same fellowship program. Additional authors may occasionally be included, if justification is provided and pre-approval by the Section Editor is granted. The order in which the authors will be listed may be decided by the authors, although it is recommended that the first author be the fellow. Although the discussions within each “Case Files” article are written in a “question & answer” format, it is not necessary that the questions will be written by the fellow and the answers by the attending. Actually, it is expected that both authors will be involved in determining the questions to be asked and in developing the responses to these question, including appropriate references from the literature.
Format for Submission:
See (Case files template) for a template of the requested submission format. The overall length of text (excluding title page, tables, figures, and references) should be in the 2500-5000 word range.
Since the opportunity to write a “Case Files” manuscript is by invitation, it is expected that each submitted manuscript will be published. However, the editors reserve the right to reject grossly inadequate submissions and/or require revisions of varying extent.
Each submitted (and accepted) manuscript will be edited initially by the Section Editor and returned to the authors for revisions/corrections. Additional editing may occur after the Section Editor has submitted the “finalized” manuscript to the Features Editor.
Case files template:
[Insert title here]:Case Files of the [Insert fellowship program name here]:
[Insert authors here, with affiliations]
Corresponding author:
[Insert corresponding author info here, including mailing address and email address]
Key words: [Insert key words here]
[Insert initial component of case here, in italics. Indent each paragraph.]
[Insert first “question” here, in bold. e.g., What are the unique characteristics of suicide attempts by physicians?]
[Insert discussion of first question here, normal font. Indent each paragraph.]
[Insert second “question” here {assuming there is a second question before the case continues}, in bold.]
[Insert discussion of second question here, normal font. Indent each paragraph.]
[Insert additional case details here, in italics. Indent each paragraph.]
[Insert additional “question” here, in bold, as above.]
[Insert discussion of additional questions here, normal font. Indent each paragraph.]
[Additional CASE CONTINUATIONs, and subsequent Q&As, may be inserted as needed.]

Letters to the Editor (Poison Pen) 

Manuscripts submitted to The Poison Pen include commentary such as observations and opinions relevant to material appearing in JMT. These should be related to articles published in the previous issue of JMT or relevant to current issues in medical toxicology. These submissions are limited to 500 words, unless permission is obtained from the editor. A maximum of three authors and twelve references are suggested. Letters discussing a JMT article should be received within 12 weeks of the article's publication. Authors of articles about which letters are received will be given the opportunity to reply, which will not be shared with the letter writer prior to publication. Abbreviated case reports are not appropriate as letters.

JMT Appeals Process for Authors 


Authors may request an appeal of publication decisions rendered by an JMT Decision Editor or the Editor-in-Chief. This policy defines the process, once the JMT Editorial office receives the appeal.
Qualifying Appeals
Appeals will be considered only if they assert that (1) an error of fact or substantial misunderstanding occurred and/or (2) a disqualifying conflict of interest exists on the part of a reviewer, the Decision Editor or Editor-in-Chief.
Appeals Process
All appeals must: (1) be made in writing to the Editor-in-Chief; (2) clearly state the basis for the appeal and provide substantiating information; and (3) be received by the JMT office within 30 days of the date of the letter of rejection.
The editorial staff will forward the appeal to the Editor-in-Chief or the Associate Editor within 5 business days. If unavailable, the Editor-in-Chief or Associate Editor may delegate this to another member of the Editorial Board not involved with initial decision.
The Editor-in-Chief, the Associate Editor, or their designee will receive the initial and revised (if applicable) manuscripts, all referee reports, and all correspondences relating to the manuscript.
The Editor-in-Chief, the Associate Editor, or their designee will choose a disposition within 30 business days of receiving the above materials. The decision may be: (1) to reaffirm the initial decision and take no further action; (2) to overturn the initial decision and accept the manuscript or write a specific revise/reconsider letter; or (3) to decide that additional information is required. If additional information is required, then the manuscript will be sent, with no other background material, to at least two reviewers not associated with the previous review, following usual manuscript review operations/timelines.
The Editor-in-Chief, the Associate Editor, or their designee will consider all referee comments at this point to choose final disposition. This decision is final and the author will be notified in writing per usual mechanisms.

Electronic Supplementary Material 

Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary files to be published online along with an article or a book chapter. This feature can add dimension to the author's article, as certain information cannot be printed or is more convenient in electronic form.
Before submitting research datasets as electronic supplementary material, authors should read the journal’s Research data policy. We encourage research data to be archived in data repositories wherever possible.


  • Supply all supplementary material in standard file formats.
  • Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
  • To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.

Audio, Video, and Animations

  • Aspect ratio: 16:9 or 4:3
  • Maximum file size: 25 GB
  • Minimum video duration: 1 sec
  • Supported file formats: avi, wmv, mp4, mov, m2p, mp2, mpg, mpeg, flv, mxf, mts, m4v, 3gp

Text and Presentations

  • Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
  • A collection of figures may also be combined in a PDF file.


  • Spreadsheets should be submitted as .csv or .xlsx files (MS Excel).

Specialized Formats

  • Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.

Collecting Multiple Files

  • It is possible to collect multiple files in a .zip or .gz file.


  • If supplying any supplementary material, the text must make specific mention of the material as a citation, similar to that of figures and tables.
  • Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online Resource 3)", “... additional data are given in Online Resource 4”.
  • Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”.


  • For each supplementary material, please supply a concise caption describing the content of the file.

Processing of supplementary files

  • Electronic supplementary material will be published as received from the author without any conversion, editing, or reformatting.


In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that
  • The manuscript contains a descriptive caption for each supplementary material
  • Video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk)

Read this Journal on Springerlink

For authors and editors

  • Aims and Scope

    Aims and Scope


    Journal of Medical Toxicology (JMT) is a peer-reviewed medical journal dedicated to advances in clinical toxicology, focusing on the diagnosis, management, and prevention of poisoning and other adverse health effects resulting from medications, chemicals, occupational and environmental substances, and biological hazards. As the official journal of the American College of Medical Toxicology (ACMT), JMT is managed by an editorial board of clinicians as well as scientists and thus publishes research that is relevant to medical toxicologists, emergency physicians, critical care specialists, pediatricians, pre-hospital providers, occupational physicians, substance abuse experts, veterinary toxicologists, and policy makers. 


    JMT articles generate considerable interest in the lay media, with 2016 JMT articles cited by various social media sites, the Boston Globe, and the Washington Post among others.

     For questions or comments about the journal, please contact jmtinfo@acmt.net.

     For questions or comments about the journal, please contact jmtinfo@acmt.net.

  • Submit Online
  • Open Choice - Your Way to Open Access
  • Instructions for Authors

    Instructions for Authors


  • Compliance with Ethical Requirements

    Compliance with Ethical Requirements


Alerts for this journal


Get the table of contents of every new issue published in Journal of Medical Toxicology.